Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Marinus (MRNS) today and set a price target of $22. The company’s shares closed yesterday at $3.80.
Piros noted:
“Given the compelling Phase 2 data announced in CDD, market size potential in PPD (with positive interim data reported in 4Q18), and undervaluation relative to peers, we believe Marinus shares offer a compelling risk-reward profile. Valuation Summary We arrive at our 12-month PT of $22/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder.”
According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -3.0% and a 43.0% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
Marinus has an analyst consensus of Strong Buy, with a price target consensus of $16.33, a 329.7% upside from current levels. In a report issued on February 25, Leerink Partners also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Marinus’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.11 million. In comparison, last year the company had a GAAP net loss of $4.74 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
